Drug intelligence / Profile preview

rabies virus glycoprotein-decorated extracellular vesicles

Development stage
Preclinical
Lead developer
University of Macau
Modality
Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

Rabies virus glycoprotein (RVG)-decorated extracellular vesicles are an engineered nanodelivery platform designed to facilitate the transport of therapeutic agents across the blood-brain barrier (BBB). The system utilizes a 29-amino acid peptide derived from the rabies virus glycoprotein, which exhibits high affinity for the nicotinic acetylcholine receptor (nAchR) expressed on brain capillary endothelial cells and neurons. By functionalizing the surface of extracellular vesicles (EVs) with this peptide, the vesicles can undergo receptor-mediated transcytosis to enter the central nervous system. This technology is primarily investigated as a modular delivery vehicle for various cargos, including small molecules like echinatin, proteins, or nucleic acids, to treat neurodegenerative conditions such as Parkinson's disease by providing targeted neuroprotection and reducing systemic side effects.

Other names
RVG-targeted extracellular vesiclesRVG-functionalized extracellular vesiclesRVG-modified exosomesRVG-decorated exosomes
02

Targets

α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)Alpha-4-beta-2-alpha-5 nicotinic acetylcholine receptorα6α3β2β3 nAChR (α6α3β2β3 nicotinic receptor)CHRNA7 (α7 nicotinic receptor)α6β2 nAChR (α6β2 nicotinic receptor)

Beyond the preview

Go deeper on rabies virus glycoprotein-decorated extracellular vesicles.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rabies virus glycoprotein-decorated extracellular vesicles.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call